Branched amphiphilic peptide capsules (BAPCs) are peptide nanospheres comprised of equimolar proportions of two branched peptide sequences bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK that self-assemble to form bi-layer delimited capsules. In two recent publications we described the lipid analogous characteristics of our BAPCs, examined their initial assembly, mode of fusion, solute encapsulation, and resizing and delineated their capability to be maintained at a specific size by storing them at 4 °C. In this report we describe the stability, size limitations of encapsulation, cellular localization, retention and, bio-distribution of the BAPCs in vivo. The ability of our constructs to retain alpha particle emitting radionuclides without any apparent leakage and their persistence in the peri-nuclear region of the cell for extended periods of time, coupled with their ease of preparation and potential tune-ability, makes them attractive as biocompatible carriers for targeted cancer therapy using particle emitting radioisotopes. This article is part of a Special Issue entitled: Interfacially active peptides and proteins.
Introduction
There is a great deal of interest in the area of nanoparticle-mediated therapies. Nanocarrier mediated targeted cellular therapy is a rapidly growing area of research for the treatment of malignant and infectious diseases. Particle emitting radioisotopes complemented with a targeting moiety are being recognized as some of the most promising cytotoxic candidates for the treatment of cancerous tumors. Nano-particles enjoy distinct advantages in the delivery of drug payloads. Their nanosizes enable them to be directly injected into systemic circulation [1, 2] and afford them longer circulating times [3, 4] . Furthermore, the circulating time can be increased by the surface modification of nano-particles with hydrophilic moieties such as polyethylene glycol [5] [6] [7] , and nanoparticles composed of biodegradable polymers can be tuned to release their drug payload in a controlled fashion; either by micelle dissociation, polymer degradation, diffusion or in combination [8] [9] [10] . Mechanisms of nanoparticle internalization into cells are influenced by their physiochemical properties. Biocompatible nanocomposites such as lipid based carriers (liposomes and micelles); polymeric vesicles designed from amphiphilic block co-polymers [11] such as polyethylene glycol-polylactic acid (PEG-PLA) and PEG-polycaprolactone (PEG-PCL) [12] ; nanocapsules [13, 14] , bola-amphiphiles (amphiphilic molecules possessing two polar heads on both sides of an aliphatic chain) such as aminoundecyltriethoxysilane (AUT) [15, 16] ; and carbon nanotubes [17] have been studied for their efficacy as delivery systems.
Liposomes are preferred over other delivery systems due to their ability to encapsulate both hydrophobic and hydrophilic contents. They can also be modified with respect to their fatty acid and head group composition, and surface alterations to modulate drug release and target affinity. Some of the issues associated with liposomes such as degradation by hydrolysis, oxidation, sedimentation, aggregation, or fusion during storage are being addressed with the development of niosomes [18] and proniosomes [19, 20] , however further testing is needed to fully establish safety and efficacy.
The selection of any nanoparticle for a specific pharmacological use is contingent on its mechanism of cellular uptake and intracellular trafficking [21] . In addition, concerns relating to the successful encapsulation of cargo, stability, specificity, bio-reactivity, biodegradability and toxicity are also relevant. The ability to release their contents is not necessarily a requirement for certain cargos. In the case of targeted alpha particle therapy (TAT) -a treatment modality for metastatic cancer and infectious diseases -the advantageous properties of 225 Ac [22] are partially offset by its systemic toxicity [23] due to the potential accumulation of its daughter nuclides in off-target sites. Utilization of alphaemitters requires containment systems that allow the high-energy alpha particles to penetrate target tissues while retaining the radionuclide and its daughter isotopes. This poses a considerable challenge since the energy (5 to 8 MeV/ 225 Ac α-particle) released is sufficient to disrupt the integrity of most traditional nano-carriers. This property has hampered the development of 225 Ac as a viable radio-therapeutic agent [24, 25] . The current use of chelating agents for 225 Ac radioimmunotherapy has been challenging as a consequence of the poorly defined coordination chemistry of Ac(III), owing to the lack of stable isotopes to enable routine chemical analysis [26] . Chelators like EDTA, DTPA, DOTA and PEPA [27, 28] have been used to complex with 225 Ac with varying degrees of success. On the other hand the potential of the otherwise promising 225 Ac-HEHA macrocyclic complex in radiotherapy [29] has been marred by instability, due to the coordinated 225 Ac radionuclide decaying into its daughter isotopes [26] .
Efforts to develop bifunctional chelators capable of stably binding 225 Ac to antibodies as well as competently containing resulting daughter nuclides at target sites, have not been successful. This has forced the development of sterically stabilized pegylated liposomes [30] and stable pegylated phosphatidylcholine-cholesterol liposomes [31] for radioimmunotherapeutic applications despite the inherent instability and retention based limitations associated with traditional liposomal systems. Moreover, novel liposomal carriers such as MUVELs (Multivesicular liposomes) -involving the passive entrapment of small vesicles into large liposomes -have been designed to enhance the targeting capabilities and the retention of alpha particle emitting daughters of 225 Ac, in an effort to better utilize their positive cytotoxic potential [32] . All of this liposome directed encapsulation techniques are however lengthy and tedious; [30] [31] [32] and involve considerable preparation times that include complex formation of 225 Ac with a chelate, annealing procedures, extended waiting periods, extrusions and centrifugation; apart from addressing various issues to counter physiochemical problems such as possible oxidation due to alpha emissions [33, 34] and beta [35] and gamma [36] radiation. The work presented herein presents an alternative and flexible means of radionuclide encapsulation that is easy to perform and generates stable in vivo constructs.
Peptide based nano-assemblies show promise as nano-delivery vehicles for the safe, targeted transport of drugs to specific tissues and organs, with minimal off target accumulation [37] by overcoming some of the problems associated with traditional lipid and viral based delivery systems. BAPCs (Branched Amphiphilic Peptide Capsules) are a new class of selfassembling peptide nano-capsular spheres [38, 39] formed during the cooperative association of a mixture of two (15-23 residue) poly-cationic branched amphiphilic peptides (Fig. 1) . The hydrophobic core sequences are derived from an internal fragment of CaIVS3, the human dihydropyridine sensitive L-type calcium channel segment [40] . The ability of the BAPCs to form bilayer-delimited spheres (Fig. 2) capable of trapping solutes is a consequence of the unique characteristics of its constituent peptides -bis(FLIVI)-K-K 4 and bis(FLIVIGSII)-K-K 4 , which reversibly transition from an alpha helical conformation in 2,2,2-Trifluoroethanol, to a beta sheet in water [38, 39] . The branch point lysine in the sequence orients the two peptide segments at ~90° angle, mimicking the geometry of diacyl phospholipids. Coarse grain molecular dynamic simulations, [38] consistent with S/TEM analysis, indicate the presence of a single capsular bilayer (3-4 nm) comparable to that of a phospholipid system, which is below the discerning resolution of electron microscopy.
Recently, we described how the flexible BAPCs possess many of the properties of phospholipid vesicles, such as fusion, solute encapsulation and an ability to be resized by membrane extrusion through polycar-bonate filters with defined pore sizes [39] . We also demonstrated several biophysical characteristics including, their mode of assembly, high thermodynamic stability, and their kinetics of fusion. The BAPCs can -like their lipid counterparts -be both resized, and maintained there by placing them at 4 °C. The versatility of these peptides to self-assemble enables us to tag individual monomers with ligands and molecular markers for a variety of analytical and functional assays, making these constructs particularly suited as biocompatible vehicles for the targeted delivery of cargo into the cells. In this report, we study the stability, cellular uptake, load capacity, retention within biological environments for extended periods of time, tolerance to a radionuclide load, biodistribution and capacity to maintain their structural integrity even when subjected to alpha particle emissions. from the C-terminus. Deprotection of the two Fmoc protecting groups leads to the generation of two reactive sites that allow for the generation of the bifurcated peptide branch point. This enables the simultaneous addition of either of the hydrophobic tail segments, FLIVI and FLIVIGSII to the common hydrophilic oligo-lysine segment by the stepwise addition of Fmoc amino acids [42] . The N-termini of the peptide were acetylated on the resin using Acetic Anhydride/N, N-Diisopropylethylamine/1-Hydroxybenzotriazole prior to cleavage. The peptide was cleaved from the resin using Trifluoroacetic acid (TFA)/H 2 O (98:2, v/v) for 90 min at RT. The released peptide product was washed 3× with diethyl ether and re-dissolved in water prior to lyophilization. The water used throughout this study is deionized, reverse osmosis treated and then distilled. The RP-HPLC purified peptides were dried in vacuo and characterized on a Bruker Ultraex III matrix-assisted laser desorption ionization time of flight mass spectrometer (MALDI TOF/TOF) (Bruker Daltonics, Billerica, MA) using 2,5-dihydroxybenzoic acid matrix (Sigma-Aldrich Corp., St. Louis, MO). The dried peptides were stored at RT. Louis, MO) in presence of N-N-Diisopropylethylamine to generate the label on the Cterminal lysine. The N α -Fmoc was de-protected and the remainder of the synthesis was carried out as indicated earlier. The labeled peptide was cleaved from the resin using standard HF cleavage protocol [44, 45] . The concentrations of all peptides were calculated using the molar extinction coefficient (ε) of phenylalanine residues (two per sequence) at 257.5 nm (195 cm −1 M −1 ) [46, 47] on a CARY 50 Bio UV/Vis spectrophotometer (Varian Inc., Palo Alto, CA) using a 0.3 cm path length quartz cuvette (Starna Cells Inc., Atascadero, CA). The Rhodamine B adducted sequences were incorporated at a prescribed mole percentage along with the unlabeled bis(FLIVI)-K-K 4 sequence of the BAPCs and utilized in fluorescence experiments.
Synthesis of

Pep-1-Pep-1 (Ac-KETWWETWWTEWSQPKKKRKV-CONH-(CH 2 ) 2 -SH) was synthesized by solid phase peptide synthesis using Fmoc-Cysteamine-SASRIN™ resin, 0.6 meq/g, (Bachem, Torrance, CA) on an Applied Biosystems 431A Peptide Synthesizer at a 0.1 mmol scale using standard Fmoc(N-(9-Fluorenyl)methoxycarbonyl)/tert-butyl chemistry as described [42] . The Fmoc amino acids used for the synthesis were obtained from Anaspec, Inc. (Fremont, CA). The N-terminal amino group was acetylated and the peptide was cleaved from the resin using TFA/water/ triisopropylsilane (94:4:2, v/v/v) for 90 min at RT to generate the C-terminal thiol. The peptide product was washed 3× with diethylether and redissolved in water prior to lyophilization. This was then purified using Reversed Phase-HPLC with 0.1% TFA/H 2 O and 0.1%TFA/90% Acetonitrile, as the binary solvent system. The purified peptide was dried in vacuo and characterized on a Bruker Ultraflex III matrix-assisted laser desorption ionization time of fiight mass spectrometer (MALDI TOF/TOF) (Bruker Daltonics, Billerica, MA) using α-Cyano-4-hydroxycinnamic acid matrix (Sigma-Aldrich Corp., St. Louis, MO). The dried peptides were stored at RT.
Capsule formation and encapsulation
The bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK peptides were dissolved individually in neat 2,2,2-Trifluoroethanol (TFE, Sigma-Aldrich Corp, St. Louis, MO). In this solvent the peptides are helical and monomeric thereby ensuring complete mixing when combined. Concentrations were determined as diluted samples in water using the absorbance of phenylalanine as described in Section 2.1.2. The bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK peptide samples were mixed in equimolar ratios to generate a fixed calculated concentration of 0.1 mM in the final volume(s), then dried in vacuo. The dried peptide samples were then hydrated to form capsules of desired concentration by the drop-wise addition of water.
HeLa cell culture
HeLa cells were obtained from Dr. Stella Y. Lee's laboratory (Division of Biology, Kansas State University) and grown in Dulbecco's minimum essential medium (Life Technologies, Grand Island, NY) with 10% fetal bovine serum. Cell cultures were passaged every 3rd-4th day by trypsinizing them using TrypLETM Express (Life Technologies, Grand Island, NY) and were kept in a humidified incubator at 37 °C and 5% CO 2 . The media were replaced every 72 h with no addition of antibiotics.
Cellular uptake of branched amphiphilic peptide capsules
2.4.1. Cellular uptake and lysosomal co-localization of BAPCs-HeLa cells were seeded on Confocal 35 mm clear petri-dishes at a density of 1 × 10 4 cells/mL and grown tõ 80% confluence and washed twice with PBS. Thereafter, 750 μL of fresh media was added along with a 250 μL aqueous suspension of BAPCs incorporating 30% Rhodamine B label on the bis(FLIVI)-K-K4 peptide. The final concentration of BAPCs was 50 μM. The cells were incubated for 4 h at 37 °C at 5% CO 2 . After a PBS wash, the cells were then incubated for 5 min with LysoTracker® Green DND-26 probe (Molecular Probes, Carlsbad, CA) at a final concentration of 75 nM and washed again with PBS. Cells were observed and images acquired using a Zeiss LSM 510 Meta Confocal Microscope (Carl Zeiss, Gottingen, Germany).
Cellular uptake of BAPCs at different temperatures-HeLa cells were
seeded on 12 mm culture dishes at a density of 1 × 10 4 cells/mL and grown to ~60% confluence. Fresh media at 4 °C and 37 °C respectively were added to the cells. Immediately thereafter, 100 μL of media was replaced by a solution of BAPCs prepared with 30% Rhodamine B label on the bis(FLIVI)-K-K 4 peptide. The final peptide concentration was 100 μM and cells were incubated for 2 h at 4 °C and 37 °C respectively. Cells were fixed with 3.7% formaldehyde at RT for 2 h, followed by a wash in PBS-T (PBS solution containing 1% Triton X-100) (Fisher Scientific LLC, Pittsburgh, PA). Subsequently, cells were incubated with Mouse Anti-β-tubulin mAb antibody [48] . 2G7D4 (Gen Script USA Inc., Piscataway, NJ) at dilutions of 1:1000 for 6 h. After three washes with PBS-T, the tissues were incubated 3 h with secondary antibody, Alexa Fluor® 488 goat anti-mouse IgG (Molecular Probes, Carlsbad, CA). Stained tissues were washed again with PBS-T and mounted in glycerol containing the nuclear stain DAPI (2 μg mL −1 ; Sigma-Aldrich Corp., St. Louis, MO). Cells were observed and images acquired using a Zeiss LSM 510 Meta Confocal Microscope (Carl Zeiss, Gottingen, Germany).
Fluorescence and confocal microscopy
Images for Fig. 2 were taken using a LSM 700 laser scanning confocal microscope (Carl Zeiss, Gottingen, Germany) and for Fig. 3 were taken using a Zeiss LSM 510 Meta Confocal Microscope (Carl Zeiss, Gottingen, Germany). The cell boundary and structure were visualized using "differential interference contrast (DIC) microscopy". All measurements, except where stated, were performed with un-fixed, live cells.
Protein uptake studies
HeLa cells were seeded into 11 mm wells (48-well plate) at a density of 1 × 10 4 cells/well and grown to roughly 60% confluence. Immediately thereafter, fresh media were added to the cells and 100 μL of the same was replaced by a solution of BAPCs containing Tcytc (5(6)-TAMRA labeled cytochrome c) and TRNase A (5(6)-TAMRA labeled RNase A) respectively. A parallel experiment was performed following the same protocol, but with Pep-1 + Tcytc and Pep-1 + TRNase A respectively, as positive controls for protein uptake. The final concentrations of peptides in each well were 50 μM for BAPCs and 5 μM for Pep-1. Cells were incubated for 3 h, washed twice with pre-warmed PBS prior to taking epifluorescence images. Subsequently, cells were trypsinized and allowed to re-attach for 18 h and images re-acquired.
Long term cellular uptake study
HeLa cells were seeded on 11 mm culture dishes at a density of 1 × 10 4 cells/well and grown to ~60% confluence. Immediately thereafter, 100 μL of media was replaced by a solution of BAPCs containing 30% Rhodamine B adducted bis(FLIVI)-K-K 4 ; with a final BAPC concentration of 100 μM. The cells were incubated at 37 °C in an atmosphere of 5% CO 2 in air. The culture was kept for 14 days after which confocal microscopy images were acquired as previously detailed. Cells were trypsinized twice during this period and the media were replaced every 72 h.
Encapsulation and retention of 225 Ac in BAPCs
The bis (FLIVIGSII)-K-K 4 and bis (FLIVI)-K-K 4 peptides (100 μM ea.) were mixed in their monomeric conformation in 50% TFE/H 2 O to ensure proper mixing and then dried. The dried peptides were rehydrated using a 0.15 M ammonium acetate buffer containing 100 μCi 225 Ac with ligand DOTA (tetraazacyclododecane-1,4,7,10-tetraacetic acid; Macrocyclics, Dallas, TX) and allowed to incubate for 2 h. Non-encapsulated radionuclide was removed by spin filtering the mixture with a 30-kDa cut-off membrane filter followed by several buffer washes. At the indicated time points, aliquots of BAPCs were withdrawn, separated from supernatant on the 30-kDa cut-off membrane filter, and the 225 Ac activity remaining in the BAPCs was quantified immediately and afterwards at 4 h to account for the daughters' decay on a 1282 Compugamma CS, Universal Gamma Counter (LKB Wallac, Gaithersburg, MD) equipped with the multi-channel analyzer using 150-600 keV energy window for 225 Ac and its daughters.
Cellular uptake of the BAPC-encapsulated 225 Ac into CasKi cells
CasKi cells (human metastatic cervical cancer cell line) were obtained from ATCC and grown as previously described [49] . BAPCs carrying 225 Ac were then used immediately to treat cells, to ensure that the BAPC diameters remain within the 50-200 nm range. Samples of 10 6 cells in triplicate were mixed with BAPC encapsulated 225 Ac; the cells were spun into pellet at 0, 1, 2, 4, 6 and 24 h, and the 225 Ac in the cellular pellet was quantified in the gamma counter as described in Section 2.8.
Biodistribution of 225 Ac and its daughter 213 Bi
All animal experiments were conducted with the permission of the Albert Einstein College of Medicine Institute for Animal Studies. 225 Ac was encapsulated into BAPCs by the addition of 500 μL 0.15 M ammonium acetate buffer with pH of 6.5 containing 60 μCi 225 Ac chloride, to 1 mM lyophilized peptides for 30 min at room temperature. After incubation the non-incorporated 225 Ac was removed by centrifugation on a microconcentrator with a 30 kDa MW cut off filter. The degree of 225 Ac incorporation into the BAPCs was calculated to be approximately 30% of the starting amount of 60 μCi. The 225 Ac-BAPCs were then diluted with sterile 0.15 M ammonium acetate buffer and eight CD-1 male mice were injected intraperitoneally (IP) with 2 μCi 225 Ac-BAPCs/100 μL. As controls eight CD-1 male mice were IP injected with 2 μCi free 225 AcCl 3 /100 μL. At 1 and 24 h post-injection, four mice from each group were humanely sacrificed and their blood, liver, kidneys and bone were removed, weighed and counted for radioactivity in a gamma counter as described previously in Section 2.8.
Results and discussion
Cellular uptake of branched amphiphilic peptide capsules
In our earlier studies we noted that synthetic branched amphiphilic peptides self-assembled to form solvent filled bilayer delimited spheres (BAPCs) that had characteristic qualities (e.g., thermal, proteolytic and chaotrope stability, cellular uptake, and low cytotoxicity) that made them potential candidates for drug delivery; and as such they might provide certain advantages over conventional lipid and/or viral based drug delivery systems [38] . Apart from carrying out a number of biophysical studies we also carried out studies that characterized the initial assembly and subsequent fusion of the BAPCs. The ability to re-size and then maintain the BAPCs at fixed sizes allowed for the generation of stable capsules that could exploit cellular fenestration and transport processes [39] . These results prompted our current studies on the cellular uptake and release capabilities of these nano-capsules. We hypothesized that cellular degradative processes would eventually cause release of the encapsulated solutes within the BAPCs. Realizing that BAPCs initially form as 20-30 nm (diameter) capsules, we also wanted to determine the maximum size of a solute that could be entrapped, as well as determine the limits of percent solute encapsulation from solution during the formation of the BAPCs. Initial studies demonstrated the loading, solute retention and cellular uptake capabilities of the BAPCs by observing the in vitro cellular colocalization of two-color fluorescence from Rhodamine B labeled BAPCs incorporating 5(6)-Carboxyfluorescein solution encapsulate.
To examine cellular uptake and intra-cellular localization of BAPCs (Fig. 3) ; 50 μM BAPCs prepared with a 30% Rhodamine B labeled bis(FLIVI)-K-K 4 were incubated with HeLa cells for 4 h; with the lysosomes stained using LysoTracker Green DND-26, as described in Section 2.4.1. As can be seen, the stained lysosomes (green) as well as the Rhodamine B labeled BAPCs (red) are visualized in the HeLa cells, in Fig. 3A and B respectively. Upon merging the two images (Fig. 3D ) both co-localized and non-co-localized BAPCs are observed, with non-co-localized particles predominating. At 2 h incubation most the BAPCs seem to be co-localized with the lysosomes (data not shown). These results indicate that BAPCs enter cells through the endosomal route yet rapidly escape the late endosomes; most likely due to lysis caused by the proposed proton-sponge effect, commonly observed for cationic particles [50] .
In another experiment (Fig. 4 ) HeLa cells were treated with the Rhodamine labeled BAPCs followed by immune-fluorescence labeling prior to fixation; to monitor uptake at two different temperatures, 4 °C and 37 °C. The cell nuclei were stained with DAPI (blue) and cellular β-Tubulin was stained with Alexa Fluor® 488 goat anti-mouse IgG (green) as previously described in Section 2.4.2 Cells incubated at 37 °C (Fig. 4B) readily took up the BAPCs while those incubated at 4 °C did not; instead the BAPCs appeared to accumulate at the cell surface (Fig. 4A) , presumably outside the cell.
These results indicate that cellular uptake is energy dependent. Endocytosis is a general mechanism of cellular uptake that is associated with receptor binding and/or attachment to the cellular membrane prior to internalization [51] . Non-endocytotic membrane fusion based uptake is known to be a function of the phase transition of the cellular lipid bilayer [52] , whereas penetration through the cellular membrane -observed with certain polycationic cell penetrating peptides -appears to proceed in an energy independent manner [53, 54] . The exact mechanism of BAPC uptake is not fully understood and might proceed via any of the above-mentioned mechanisms; however it seems conceivable based on lysosomal colocalization and temperature dependent uptake data, that BAPCs are internalized by the cellular machinery via an energy dependent endocytotic pathway. The mechanistic studies of BAPC uptake were however not the main thrust of this work.
Encapsulation and retention
Early in our work with BAPCs, we tried to encapsulate several small proteins, namely TAMRA-labeled RNase A (TRNase A, 13.7 kDa), and TAMRA-labeled cytochrome c (Tcytc, ~12 kDa), as well as the intrinsically fluorescent EGFP (26.9 kDa). These experiments were designed to test whether the BAPCs could deliver and then release the TAMRA-labeled proteins to induce a measurable cytotoxic effect. Both cytochrome c and RNase A were successfully encapsulated in the BAPCs while the EGFP which has a tendency to aggregate in water was not. In Sukthankar et al., S/TEM studies with BAPCs adducted with methyl-mercury showed that nascent BAPCs are formed with an average diameter of 20-22 nm and a calculated internal volume of 4000 nm 3 [39] . BAPCs individually loaded with Tcytc or TRNase A were incubated with HeLa cells for 3 h. Pep-1, an amphipathic cell penetrating peptide carrier capable of inducing cellular uptake of a variety of proteins and peptides into cell lines with a high degree of efficiency [55] , was employed as a control delivery agent for Tcytc [56] and TRNase A. Fig. 5 demonstrates the ability of the BAPCs to encapsulate and deliver both Tcytc and TRNase A into HeLa cells. In these representative images, the efficiency of Tcytc transport with BAPCs (Fig. 5A) is slightly less than that with Pep-1 (Fig. 5B) ; however in the case of TRNase A there is no significant difference between the carrying capacity of the BAPCs (Fig. 5C ) versus Pep-1 (Fig. 5D ). Cytochrome c [57] and RNase A [58] are both known to effect cellular apoptosis. Interestingly enough, no significant cellular apoptosis was observed in the case of either of the proteins taken up by HeLa cells using BAPCs; while Pep-1 mediated transport led to frank cytotoxicity in the expected manner (data not shown).
The ability of the BAPCs to persist within HeLa cells was then examined over a longer time period. A confocal microscopy based study conducted using HeLa cells treated with Rhodamine B labeled BAPCs (Fig. 6 ) revealed that even after 14 days, the BAPCs persist within the cells and are transferred to daughter cells during mitosis without any apparent degradation. The degradation of the BAPCs labeled with Rhodamine B would tend to proceed with a dispersion of the dye/dye-peptide fragments and/or an increase in the fluorescence intensity of Rhodamine B due to a change in its local environment [59] . None of these characteristics indicative of nanoparticles degrading within the cell were observed. This would -in retrospect -be consistent with expectation as cationic nano-particles, especially those containing poly-lysine tend to escape and/or evade lysosomal degradation by charge destabilizing the endo-lysosomal membranes [60] . It seems that the cellular machinery is unable to breakdown the BAPCs. In designing the BAPCs, we anticipated that they would be able to release cargo within the cytoplasm or a cellular compartment. However, the inability of the peptide capsules to do so makes our constructs, in their current design, too stable for conventional targeted drug delivery. The peptides that constitute the BAPCs were designed to mimic diacyl phospholipids in molecular architecture. However, unlike liposomes where the non-solvated tail groups are held together primarily by hydrophobic interactions, BAPCs have the additional component of hydrogen bonding; as well as inter-and intra-molecular pi-stacking (π-π) between the phenylalanine aromatic rings of peptide sequences that apparently imbues the capsules with remarkable stability.
Encapsulation of radionuclides using BAPCs
Given the ability of BAPCs to take up but not release cargo, and their persistence in cells for extended periods of time suggested a potential application -α-particle therapy. Targeted α-particle therapy, using particle-emitting radionuclides holds promise as therapeutic agents in treating micrometastases [61] . The effectiveness of this therapy is a function of the α-particle's properties. They are emitted with energies in the MeV range, with Linear Energy Transfer (LET) having a mean energy deposition of 100 keV/μm, enabling them to produce more lethal DNA breaks per radiation track as compared to β − -particles in the cell nucleus. It has been estimated that a few α-particle transversals are sufficient to kill a cell [62] . The limited range of α-particles (50-100 μm) confines their toxicity to a small radius from the site of the isotope decay, enabling more specific tumor killing capability without damage to the surrounding normal tissue; as opposed to β − -particles, which have a much longer range [26] . Furthermore the cytocidal effectiveness of α-particles has been shown to be independent of oxygen concentration [63] , dose rate and cell cycle position [64] . Additionally, studies performed on a leukemia model indicated that α-emitter radionuclides exhibited cytotoxicity superior to that of β − -radiation or γ-radiation and are capable of killing cancer cells which are resistant to chemotherapeutic drugs such as doxorubicin [65] .
Targeted alpha particle therapy
There are a number of α-emitter radionuclides, one of which, 213 Bi (t 1/2 = 46 min), has been proposed for therapeutic use and clinically evaluated. However, 213 Bi is generator produced and has a relatively short half-life requiring very rapid tumor targeting. An alternative then involves utilizing 225 Ac, which is the parent nuclide of 213 Bi. A single 225 Ac (t 1/2 = 9.9 days) generates four alpha and three beta particles during its disintegration, along with two useful gamma emissions, including the 221 keV of 221 Fr and the 440 keV of 213 Bi (Fig. 7) , that can be used for in vivo imaging [66, 67] . The enhanced potency of 225 Ac as opposed to 213 Bi has been demonstrated in several pre-clinical studies [65, 68] . Ongoing research has focused on harnessing the cell-killing power of these radionuclides by directing them to metastatic cells via appropriate targeting vectors. 225 Ac decay proceeds via a succession of daughter isotopes. This decay releases 28 MeV of energy in the form of α-particles. However, for the sake of optimal killing efficiency, the α-emissions and therefore the 225 Ac atom, must be delivered precisely and only to the region of interest. A problem closely associated with the 'targeting nanogenerator approach' [69] which involves stably chelating the 225 Ac for delivery in vivo is that, after the initial 225 Ac decay to 221 Fr, the co-ordinate bonds from the chelating ligand to the central metal atom are not retained. Thus the daughter isotopes distribute freely within the body causing unwanted cytotoxicity.
Therefore it is desirable to confine the daughter isotopes of 225 Ac within the carrier during circulation and targeting. This problem is compounded by the fact that the high kinetic energy of the α-particle emissions penetrates the phospholipid membrane in liposomes, which could otherwise be considered as suitable candidates for encapsulated delivery. Moreover, the recoil trajectory of the daughter nuclides (80-90 nm) penetrates the phospholipid membranes causing rupture and leakage [31] leading to escape and redistribution within the body, increasing toxicity. Retention of daughter isotopes is size dependent. Theoretical calculations by Sofou et al. [33] suggest negligible (<0.001%) daughter retention for the last isotope for 100 nm diameter liposomes and 50% retention of the same for liposomes with a diameter larger than 650 nm. Even for giant liposomes (1 μm diameter), retention does not exceed 65%. The measured last daughter retention for the 650 nm liposomes was found to be substantially lower (11%) than what was calculated, owing to the tendency of 225 Ac to bind to the negatively charged phospholipid membrane leading to non-uniform distribution within the liposome causing daughter loss after recoil. The large size of such liposomes required to carry effective loads has serious limitations with regard to fenestration and cellular uptake. This coupled with low daughter retention capabilities makes them a cumbersome system for efficient targeted radiotherapy. Considering the stability, uptake and retentive capabilities of the BAPCs; they were tested as a potential 225 Ac carrier for targeted alpha particle therapy applications.
Radio-therapeutic potential of BAPCs
Experiments were performed to monitor encapsulation of 225 Ac into BAPCs, as well as its retention within them over 7 days. Uptake of BAPC-encapsulated 225 Ac was then tested in vitro using human metastatic cervical cancer (CasKi) cells. The 225 Ac was well contained by the BAPCs, with retention being ≥95% of the original activity for the period of 7 days (Fig.  8A) . The cellular uptake of encapsulated 225 Ac increased in a time dependent manner and reached 33% at 24 h post incubation (Fig. 8B) . It is important to note that a much lower dose of 225 Ac (0.1 μCi) was used for this uptake experiment to avoid any cytocidal effects on the cells that could cloud the cellular uptake results. These findings were encouraging as they demonstrated the potential of BAPCs as candidates for 225 Ac encapsulation and cellular uptake.
Biodistribution of BAPCs encapsulating 225 Ac
To investigate the behavior of BAPCs in vivo we studied the distribution of BAPC encapsulated 225 Ac and its daughter 213 Bi (along with a control of free 225 AcCl 3 and 213 Bi), in CD1 mice at 1 and 24 h post IP administration. Tissues were collected and analyzed at the indicated times. The 440 keV γ-emission of 213 Bi was used to calculate the percentage of the injected dose per gram of organ (ID/g organ, %) as described in Section 2.10. In Fig. 9 we see the results of the in vivo distribution in mice for free 213 Bi/ 225 Ac versus encapsulated material. At 1 h post injection, when both 'BAPC encapsulated 225 Ac' and 'free 225 Ac' were still in the process of exiting the peritoneal cavity, there was no significant difference in organ uptake between BAPC encapsulated 225 Ac and free 225 Ac (except for bone, where free 225 Ac is known to accumulate). The uptake of 225 Ac daughter 213 Bi into the kidneys was higher than that of 225 Ac, as free 213 Bi targets kidneys. The differences between BAPC encapsulated 225 Ac, and free 225 Ac became more pronounced at 24 h post injection. The free 225 Ac is completely cleared from the blood via binding to the plasma proteins and being delivered to various organs. BAPC encapsulated 225 Ac stayed in circulation due to the small size of the BAPCs, consistent with nanomaterials in the 10-20 nm size range that tend to stay in circulation. Free 225 Ac accumulated significantly more in the liver (P = 0.03) and in the bone (P = 0.02) than the BAPC encapsulated 225 Ac. This confirms the tight retention of 225 Ac within the vesicles. 213 Bi daughter was present together with 225 Ac pointing to retention of the daughters by the BAPCs as well. The only organ where there was more 213 Bi present in comparison with 225 Ac were the kidneys -which serve as the 'sink' for 213 Bi that has been released from any organ in the body. Overall, encapsulated 225 Ac cleared much more from the body than 'free 225 Ac' through the combination of renal, hepatobiliary and intestinal goblet cell (GC) secretion (IGCSP) pathways [70] . Taken together, these results point to the ability of BAPCs to incorporate and retain 225 Ac and its daughter isotopes through 213 Bi.
Conclusion
It is evident that the extraordinary stability of the BAPCs, in their current design, limits their use as a drug delivery modality. However, this same characteristic makes them appear ideal for targeted alpha particle therapy for the treatment of metastatic and infectious diseases. Our results show that alpha the emitting radionuclide 225 Ac, and its radioactive daughters, can be sequestered within the lumen of the BAPCs and then retained for days (and through multiple cell divisions), just outside the nucleus of the cell. This portends well for cytocidal effects.
The fact that BAPCs withstand rupture from the ejected high energy alpha particles and the resulting recoil of the daughter isotope, suggests a self-annealing property for BAPCs. It is likely that BAPCs are taken up by cells through a non-selective internalization process, possibly proceeding via transient pore formation, analogous to that observed with some polycationic lipids [71] and polymers [72] . Should this assessment be accurate; the BAPCs would be able to find utility as nano-carriers in cellular systems. The poly-lysine cationic surface of the BAPCs provides a convenient synthetic pathway for the modification and conjugation of ligands, antibodies and molecular markers to achieve cellular targeting. This could greatly reduce the whole body load required to kill desired cells as well as reduce deleterious off-target side effects. The fact that the capsules also remain in circulation for an extended period most likely reflects their small size and flexibility. The ability of the BAPCs to persist in cells through cell division(s) suggests a potential use as cell lineage tracers and probes. BAPCs could be conjugated to quantum dots in an effort to resolve some of the biocompatibility issues associated with the latter [73] . The BAPCs constitute a unique and exciting new class of biomaterial, which while portending promise as a convenient agent for targeted alpha particle therapy, could find application in many other areas as well. Bilayer forming branched amphiphilic peptide sequences. S/TEM image of BAPCs. They containing 30% Hg label and imaged at 2 h post hydration w/negative glow discharge and uranyl acetate staining prepared as previously described [39] . Long term cell uptake study. HeLa cells incubated with BAPCs with a 30% Rhodamine B label on bis(FLIVI)-K-K 4 , observed after 2 weeks using confocal microscopy through two trypsinizations. A) Dark field image with channel selected for the excitation of Rhodamine; B) bright-field image; C) overlap of the bright-field image and channel for Rhodamine. The proposed decay scheme for 225 Ac based on the recently published studies [64, 65] . Biodistribution of free and BAPC-encapsulated, 225 Ac and its daughter 213 Bi, in CD1 mice. A) 1 h time point; B) 24 h time point.
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